Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Basal Insulin and IV Insulin in Hyperglycemic Crisis
NCT05155917Phase 2Unknown
- Sponsor
- Changhua Christian Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin glargine in diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) (2 arms), sponsored by Changhua Christian Hospital. Primary endpoints: Rates of Rebound Hyperglycemia and Rates of Hypoglycemia. Status: unknown.
02
Drugs
insulin glargine
03
Conditions
diabetic ketoacidosis (DKA)hyperosmolar hyperglycemic state (HHS)
Beyond the preview
Go deeper on NCT05155917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155917.